Up next

DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

2025: The Bio/Pharma Industry’s Year in Review

By
Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?

UK, US Strike Agreement for Drug Pricing & Tariffs

By
The UK and the US governments have agreed in principle on drug pricing and tariffs/trade on pharmaceuticals between the two countries, months after the countries formed an initial trade pact. What is the new deal and the impact on pharma?

Raising the Bar: The Innovation Leaders

By
Innovation is central to the bio/pharma industry, so what have been the key developments in 2025? Which companies and their innovation stand out? DCAT Value Chain Insights takes an inside look.

Global Impact: US Tariffs, Pharma & GDP

By
What has been the impact of US tariffs thus far on global trade, including on pharmaceuticals and pharmaceutical ingredients? Plus, Switzerland is the latest country to strike a new tariff deal.